Carl Chiang

North Carolina Institute of Medicine — United States

Medicine · Health Sciences

8h-index1.2kcitations26works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dementia and Cognitive Impairment Research(12), Computational Drug Discovery Methods(5), Bioinformatics and Genomic Networks(5), Neural dynamics and brain function(3), Cholinesterase and Neurodegenerative Diseases(3)

Publications26 total

Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency
Neurology·2025· 4 citedOpen Access
71PSafety of pyrimidine nucleos(t)ide therapy in Thymidine kinase 2 deficiency: an integrated analysis from a pooled dataset
Neuromuscular Disorders·2025· 1 cited
Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trial
Research Square (Research Square)·2021· 1 citedOpen Access
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2021· 108 cited
A genetic enrichment strategy for delay of onset of Alzheimer’s disease clinical trials
Alzheimer s & Dementia·2020Open Access
O4‐11‐02: DEFINING COGNITION IN PRE‐DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY
Alzheimer s & Dementia·2019
DT‐02‐02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM
Alzheimer s & Dementia·2019· 4 citedOpen Access
The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial
Alzheimer s & Dementia Translational Research & Clinical Interventions·2019· 41 citedOpen Access
P1‐050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAY‐OF‐ONSET PHASE 3 CLINICAL TRIAL
Alzheimer s & Dementia·2018
TOMMORROW neuropsychological battery: German language validation and normative study
Alzheimer s & Dementia Translational Research & Clinical Interventions·2018· 11 citedOpen Access
[P1–059]: APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY‐OF‐ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER's DISEASE (MCI‐AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE
Alzheimer s & Dementia·2017
P4‐383: Characterization of the Screened Population for the Tommorrow Study: a Pharmacogenetics‐Supported Clinical Trial to Delay the Onset of Mild Cognitive Impairment Due to Alzheimer’S Disease
Alzheimer s & Dementia·2016
P4‐395: Clinical Trials in the Preclinical to MCI Stages of AD: Cross‐Cultural Validation and Normative Study of the Tommorrow Neuropsychological Battery
Alzheimer s & Dementia·2016
P2‐083: Progress in the tommorrow study: A pharmacogenetics supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease with low‐dose pioglitazone
Alzheimer s & Dementia·2015Open Access
P2‐392: CROSS‐CULTURAL VALIDATION AND NORMATIVE STUDY OF A NEUROPSYCHOLOGICAL BATTERY USED IN THE DETERMINATION OF CLINICAL ENDPOINTS TO DELAY ONSET OF MCI
Alzheimer s & Dementia·2014
P4‐073: A PHARMACOGENETICS‐SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW‐DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY
Alzheimer s & Dementia·2014· 3 cited
O1–06–01: Challenges in international clinical trials to delay early symptomatic Alzheimer's disease
Alzheimer s & Dementia·2013· 5 cited
P4–065: A pharmacogenetics‐supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease
Alzheimer s & Dementia·2013· 2 cited
P4‐269: A pharmacogenetic‐supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD)
Alzheimer s & Dementia·2012· 14 citedOpen Access
Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research·2011· 192 cited
page 1 of 2Next →

Frequent Co-authors

Daniel K. Burns(16), Kathleen A. Welsh‐Bohmer(16), Ann M. Saunders(14), Janet O’Neil(13), Brenda L. Plassman(11), Meredith Culp(10), Michael W. Lutz(9), Stephen Haneline(9), Craig A. Metz(8), Grant Runyan(7), Deborah Yarbrough(7), Allen D. Roses(7), Stephen K. Brannan(6), Heather Romero(6), Kathleen M. Hayden(6), Alexandra S. Atkins(6), Richard S.E. Keefe(6), Robert Alexander(5), Patrick J. Harrigan(5), Andreas U. Monsch(5)